Info
CReATe Connect podcasts are short recorded interviews on topics we hope will be of interest to patients with ALS and other motor neuron diseases.
Episodes & Posts
Episodes
Posts
Transcribed
15 MAY 2026 · ISRIB stands for “integrated stress response inhibitor). As we discuss here, it is an oral medication that inhibits an intracellular pathway called the integrative stress response pathway. It is not FDA approved for any condition but is available in Spain without a prescription. There are theoretical ways that inhibiting this pathway could help a person with ALS, and there is promising data from preclinical ALS models. However, it is not clear that ISRIB is soluble enough to get into motor neurons in the brain and spinal cord, and 2 of 3 trials of agents targeting the same pathway failed to show any benefits in people with ALS. The risks of this product in ALS are not known.
9 APR 2026 · Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. Here he discusses the recent publication “Proposed Research Criteria for Mild Motor Impairment as a Prodromal Syndrome in Amyotrophic Lateral Sclerosis."
8 JAN 2026 · Here we have a podcast produced by artificial intelligence discussing the recent publication “Design considerations for C9orf72 disease prevention trials”.
10 DEC 2025 · The Wahls Protocol is a diet that may reduce inflammation, oxidative stress, and mitochondrial dysfunction. Although these are plausible mechanisms for slowing ALS progression, we discuss the fact that there are no actual data to support this hypothesis, and there are risks which are especially important to consider in people living with ALS.
17 NOV 2025 · Psilocybin is a psychedelic chemical derived from mushrooms. It is under study for mood problems in people with ALS. Here we review its plausible mechanisms for slowing ALS progression. But there are no data from preclinical models, trials or case reports that currently support this benefit. And there can be serious risks to using this chemical.
20 OCT 2025 · Here we review ashwagandha a nutritional supplement that has plausible mechanisms for slowing ALS, promising pre-clinical evidence, and a reasonable safety profile. There is one person with ALS who experienced a reversal of symptoms on a cocktail of treatments that included ashwagandha. Cases like this are difficult to interpret as there can be multiple explanations for a person experiencing an ALS reversal. We have not found any other cases suggesting improvement on this product. We hope to see the data from the completed phase 2 trial soon.
24 SEP 2025 · Dr. Johnathan Cooper-Knock is a neurologist and clinical lecturer at the University of Sheffield. His research focuses on genetic causes of ALS. Here he discusses his recent publication “Extreme exercise in males is linked to mTOR signalling and onset of amyotrophic lateral sclerosis”.
9 SEP 2025 · Here we review Zinc supplements as a treatment for ALS. These are inexpensive, reasonably safe at certain doses, and are easy to acquire. They have plausible mechanisms by which they could slow ALS progression. However, the data from people living with ALS is not very convincing yet.
2 JUN 2025 · Dr. Terry Heiman-Patterson is a neurologist and professor at Temple University and the director of the Center for Neurodegenerative Disorders and the MDA/ALS Center of Hope. Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. In this podcast they will be discussing their recent publication “Guidance for clinical management of pathogenic variant carriers at elevated genetic risk for ALS/FTD”.
1 MAY 2025 · Dr. Ruben van Eijk is an associate professor in the Department of Neurology at the University Medical Center Utrecht in the Netherlands as well as a statistical consultant and medical statistician for the clinical trial methodology group at the Julius Center also in Utrecht. Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. They will be discussing their recent publication “Rethinking phase 2 trials in amyotrophic lateral sclerosis”.
CReATe Connect podcasts are short recorded interviews on topics we hope will be of interest to patients with ALS and other motor neuron diseases.
Information
| Author | CReATe Consortium |
| Organization | CReATe Consortium |
| Categories | Health & Fitness |
| Website | - |
| - |
Copyright 2026 - Spreaker Inc. an iHeartMedia Company
